Published in J Allergy Clin Immunol on October 01, 1992
Induction of tachykinin gene and peptide expression in guinea pig nodose primary afferent neurons by allergic airway inflammation. J Clin Invest (1996) 1.38
Brain-derived neurotrophic factor (BDNF) contributes to neuronal dysfunction in a model of allergic airway inflammation. Br J Pharmacol (2004) 1.12
Inflammation-induced plasticity of the afferent innervation of the airways. Environ Health Perspect (2001) 1.00
Neurogenic inflammation in human airways: is it important? Thorax (1995) 0.89
Substance P receptor blockade decreases stretch-induced lung cytokines and lung injury in rats. J Physiol (2010) 0.89
Neurokinin A is the predominant tachykinin in human bronchoalveolar lavage fluid in normal and asthmatic subjects. Thorax (1998) 0.83
Neurogenic inflammation in lung disease: burnt out? Inflammopharmacology (1997) 0.81
Significance of Conversation between Mast Cells and Nerves. Allergy Asthma Clin Immunol (2005) 0.81
Differential reactivity of human bronchoalveolar lavage mast cells to substance P. Agents Actions (1994) 0.79
Expression and function of human hemokinin-1 in human and guinea pig airways. Respir Res (2010) 0.78
Substance P downregulates expression of the high affinity IgE receptor (FcepsilonRI) by human mast cells. J Neuroimmunol (2010) 0.78
Upregulation of neurokinin-1 receptor expression in the lungs of patients with sarcoidosis. J Clin Immunol (2003) 0.78
Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. J Allergy Clin Immunol (2016) 0.77
Role of tachykinin NK2-receptor activation in the allergen-induced late asthmatic reaction, airway hyperreactivity and airway inflammatory cell influx in conscious, unrestrained guinea-pigs. Br J Pharmacol (1999) 0.77
Diacetyl increases sensory innervation and substance P production in rat trachea. Toxicol Pathol (2013) 0.76
Involvement of tachykinin receptors in sensitisation to cow's milk proteins in guinea pigs. Gut (1999) 0.76
Mas-related G protein coupled receptor-X2: A potential new target for modulating mast cell-mediated allergic and inflammatory diseases. J Immunobiol (2016) 0.75
Substance P/Neurokinin 1 and Trigeminal System: A Possible Link to the Pathogenesis in Sudden Perinatal Deaths. Front Neurol (2017) 0.75
Acid-Sensing Ion Channel 1a Contributes to Airway Hyperreactivity in Mice. PLoS One (2016) 0.75
Decreased vascular permeability response to substance P in airways of genetically hypertensive rats. Br J Pharmacol (1999) 0.75
Models of toxicity of diacetyl and alternative diones. Toxicology (2017) 0.75
Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin. J Physiol (1983) 2.42
The effects of substance P on histamine and 5-hydroxytryptamine release in the rat. J Physiol (1982) 1.88
The production, storage and release of the neurotrophins nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 by human peripheral eosinophils in allergics and non-allergics. Clin Exp Allergy (2003) 1.59
Omalizumab inhibits allergen challenge-induced nasal response. Eur Respir J (2004) 1.56
Activation of the specific neurotrophin receptors TrkA, TrkB and TrkC influences the function of eosinophils. Clin Exp Allergy (2002) 1.47
Topical vasoconstrictor (oxymetazoline) does not affect histamine-induced mucosal exudation of plasma in human nasal airways. Clin Exp Allergy (1992) 1.42
CAPD: developments during changing times. Perit Dial Int (2009) 1.38
Cutaneous expression of CRH and CRH-R. Is there a "skin stress response system?". Ann N Y Acad Sci (1999) 1.18
[Allergies to animal hair in diseases of the upper respiratory tract (author's transl)]. Dtsch Med Wochenschr (1975) 1.08
Semihistone protein A24 replaces H2A as an integral component of the nucleosome histone core. Proc Natl Acad Sci U S A (1979) 1.08
Dermal and bronchial hyperreactivity in urticarial dermographism and urticaria factitia. Allergy (1996) 1.06
Reversibility and reproducibility of histamine induced plasma leakage in nasal airways. Thorax (1989) 1.03
The influence of inhalative corticosteroids on circulating Nerve Growth Factor, Brain-Derived Neurotrophic Factor and Neurotrophin-3 in allergic asthmatics. Clin Exp Allergy (2001) 1.01
Hair cycle-dependent expression of corticotropin-releasing factor (CRF) and CRF receptors in murine skin. FASEB J (1998) 0.99
Influx of kininogens into nasal secretions after antigen challenge of allergic individuals. J Clin Invest (1985) 0.99
A role for a helical connector between two receptor binding sites of a long-chain peptide hormone. J Biol Chem (2000) 0.99
Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol (1993) 0.99
Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain. Br J Pharmacol (2007) 0.99
Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Mol Pharmacol (2000) 0.97
Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J (1992) 0.97
Differential expression of SNAP-25 isoforms and SNAP-23 in the adrenal gland. J Neurochem (1999) 0.96
Hair growth induction by substance P. Lab Invest (1994) 0.96
Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J (2003) 0.95
Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. Allergy (2006) 0.93
Influence of ozone and nitrogen dioxide on histamine and interleukin formation in a human nasal mucosa culture system. Am J Respir Cell Mol Biol (1999) 0.92
Kinin metabolism in human nasal secretions during experimentally induced allergic rhinitis. J Immunol (1987) 0.92
Histopathological Examinations of nasal polyps of different etiology. Arch Otorhinolaryngol (1980) 0.92
Concentrations of glandular kallikrein in human nasal secretions increase during experimentally induced allergic rhinitis. J Immunol (1986) 0.91
A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor. J Med Chem (1996) 0.91
A selective tonic activation of gastrointestinal smooth muscle by substance P. Arch Int Pharmacodyn Ther (1978) 0.90
Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol (1997) 0.89
Comparison between MAGIC LITE- and CAP-system: two automated specific IgE antibody assays. Clin Exp Allergy (1992) 0.89
Day-night patterns in bronchial patency and dyspnea: basis for once-daily and unequally divided twice-daily theophylline dosing schedules. Chronobiol Int (1987) 0.89
Tryptase in nasal lavage fluid after local allergen challenge. Relationship to histamine levels and TAME-esterase activity. Allergy (1991) 0.88
Plasma kallikrein during experimentally induced allergic rhinitis: role in kinin formation and contribution to TAME-esterase activity in nasal secretions. J Immunol (1986) 0.88
Contralateral differences among biomarkers determined by a modified nasal lavage technique after unilateral antigen challenge. Allergy (1995) 0.85
Antioxidative enzymes in human nasal mucosa after exposure to ozone. Possible role of GSTM1 deficiency. Inflamm Res (2003) 0.84
Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. Clin Exp Allergy (1993) 0.84
Neutral endopeptidase 24.11: its physiologic and possibly pathophysiologic role in inflammation with special effect on respiratory inflammation. Allergy (1998) 0.83
Regulation of beta-adrenergic receptors on endothelial cells in culture. Eur Heart J (1993) 0.83
Substance P: does it produce analgesia or hyperalgesia? Science (1980) 0.83
Comparison of the Phadebas RAST with the Pharmacia CAP system for insect venom. Allergy (1992) 0.83
Polyphosphoinositide metabolism in erythrocytes of spontaneously hypertensive rats. Biochem Pharmacol (1981) 0.83
The role of conserved extracellular cysteine residues in vasopressin V2 receptor function and properties of two naturally occurring mutant receptors with additional extracellular cysteine residues. FEBS Lett (2000) 0.82
Effects of voluntary ethanol ingestion on the POMC gene expression in the rat pituitary and on the plasma beta-endorphin content. Alcohol Alcohol (1995) 0.82
Corticotropin-releasing factor (CRF) agonists stimulate testosterone production in mouse leydig cells through CRF receptor-1. Endocrinology (1998) 0.82
Corticotropin-releasing hormone (CRH) receptors in the mesenteric small arteries of rats resemble the (2)-subtype. Biochem Pharmacol (1996) 0.82
Glucocorticoids and protein kinase C regulate neutral endopeptidase 24.11 in human vascular smooth muscle cells. Basic Res Cardiol (1998) 0.82
Hypertrophic pulmonary osteoarthropathy and venous admixture. Klin Wochenschr (1971) 0.82
Multiple IgE-mediated sensitizations to enzymes after occupational exposure: evaluation by skin prick test, RAST, and immunoblot. Allergy (1997) 0.82
A bovine brain fraction with fibroblast growth factor activity inducing articular cartilage regeneration in vivo. Acta Biol Med Ger (1980) 0.81
Cortisol and beta-endorphin response in alcoholics and alcohol abusers following a high naloxone dosage. Drug Alcohol Depend (1990) 0.81
Localized "radiation hepatitis" as demonstrated by scintillation scanning. Radiology (1967) 0.81
Results of biological standardization with standardized allergen preparations. Allergy (1987) 0.81
[Inactivation of pharmacologically active peptides by hemolysate fractions]. Acta Biol Med Ger (1968) 0.81
Demonstration of angiogenesis-activity in the corpus luteum of cattle. Exp Pathol (Jena) (1977) 0.81
Circular dichroism studies of substance P and its C-terminal sequences. CD spectra in aqueous solution and effects of hydrogen ion concentration. Int J Pept Protein Res (1980) 0.81
Use of CD34+ autologous stem cell transplantation in the treatment of children with refractory systemic lupus erythematosus. Clin Rheumatol (2005) 0.81
Substance P induced histamine release from nasal mucosa of subjects with and without allergic rhinitis. Inflamm Res (2000) 0.81
[3 cases of intravitally diagnosed Wegener's granulomatosis. Diagnosis, course and therapy]. Dtsch Med Wochenschr (1969) 0.80
The essential sequence of substance P for locomotion. Pharmazie (1986) 0.80
Role of the major allergen (Fel d I) in patients sensitized to cat allergens. Int Arch Allergy Immunol (1993) 0.80
Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol (2011) 0.80
Changes in non-specific nasal reactivity and eosinophil influx and activation after allergen challenge. Clin Exp Allergy (1990) 0.80
Bradykinin and other inflammatory mediators in BAL-fluid from patients with active pulmonary inflammation. Agents Actions Suppl (1992) 0.80
Reduction of plasma catecholamines in humans during clinically controlled severe underfeeding. Prev Med (2000) 0.79
[The role of the N-terminal of the substance P molecule in its action in stress-related behavioral and blood pressure disorders]. Pharmazie (1986) 0.79
Evidence of decreased plasma substance P levels in human essential hypertension and influence of prazosin treatment. Biomed Biochim Acta (1983) 0.79
Effect of fluticasone on neuropeptides in nasal lavage in persistent allergic rhinitis. J Investig Allergol Clin Immunol (2010) 0.79
Adaptation of corticosterone-but not beta-endorphin-secretion to repeated blood sampling in rats. Lab Anim (1999) 0.79
Bronchial hyperreactivity in patients with moderate pulmonary circulation overload. Chest (1993) 0.79
Effect of substance P (SP) and the N-terminal SP-analogue SP (1-4) on the pre- and postsynaptic transmitter release in rat adrenal gland slices. Biomed Biochim Acta (1987) 0.79
Modified T-cell activation pattern during specific immunotherapy (SIT) in cat-allergic patients. Clin Exp Allergy (1999) 0.79
Responses of guinea-pig gastric, ileal and gall bladder smooth muscle to desamino-cholecystokinin-octapeptide (CCK 7). Methods Find Exp Clin Pharmacol (1988) 0.79
Nasal challenge studies with bradykinin: influence upon mediator generation. Clin Exp Allergy (1991) 0.79
Radioimmunoassay of corticotropin-releasing hormone. Exp Clin Endocrinol (1990) 0.78
The possible role of bradykinin as a mediator in bronchial asthma. Allergol Immunopathol (Madr) (1983) 0.78
Evidence for downregulation of the endothelin-B-receptor by the use of fluorescent endothelin-1 and a fusion protein consisting of the endothelin-B-receptor and the green fluorescent protein. J Cardiovasc Pharmacol (2000) 0.78
Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis. J Allergy Clin Immunol (1989) 0.78
Modulation of locomotor activity by substance P in rats. Regul Pept (1983) 0.78
Does a relationship exist between the quality of stress and the motivation to ingest alcohol? Alcohol (1994) 0.78
Nicotinic stimulation of polyphosphoinositide turnover in rat adrenal medulla slices. Pharmazie (1987) 0.78
Effect of angiotensin-converting-enzyme inhibition on bradykinin metabolism by vascular endothelial cells. Am J Physiol (1993) 0.78
[32P'incorporation into polyphosphoinositides of erythrocytes from essential hypertension]. Acta Biol Med Ger (1981) 0.78
Substance P enhances antigen-evoked mediator release from human nasal mucosa. Peptides (1996) 0.78
Predominance of the major allergen (Alt a I) in Alternaria sensitized patients. Clin Exp Allergy (1993) 0.78
Substance P is generated in vivo following nasal challenge of allergic individuals with bradykinin. Clin Exp Allergy (1997) 0.78
Gelatin sponge-supported histoculture of human nasal mucosa. In Vitro Cell Dev Biol Anim (1995) 0.77
Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy (1998) 0.77
Comparison of the bronchodilating efficacies of a novel salbutamol metered dose powder inhaler and a pressurised metered dose aerosol with a spacer. Arzneimittelforschung (1998) 0.77
Substance P-like immunoreactivity in plasma and adrenal medulla of rats with spontaneous hypertension and WKY rats under acute stress. Biomed Biochim Acta (1983) 0.77
Mediator release is altered in immunotherapy-treated patients: a 4-year study. Allergy (1996) 0.77
Activation of adenylate cyclase and phosphodiesterase inhibition enhance neutral endopeptidase activity in human endothelial cells. Peptides (1995) 0.77
Effects of fexofenadine on inflammatory mediators in nasal lavage fluid in intermittent allergic rhinitis. J Investig Allergol Clin Immunol (2009) 0.77